AIM ImmunoTech (AIM) Other financing activities (2026)
AIM ImmunoTech's (AIM) quarterly Other financing activities came in at $2.2 million in Q1 2026.
AIM ImmunoTech (AIM) Other financing activities (2026) Analysis & Trends
AIM ImmunoTech (AIM) has 1 years of Other financing activities data on file, last reported at $2.2 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - |
| 10 | AIM ImmunoTech | 4.47 Mn | -5.49 Mn | 21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.58 Mn |
| Jun 30, 2026 | 3.58 Mn |
| Mar 31, 2026 | 2.16 Mn |
| Mar 31, 2026 | 2.16 Mn |